Targeting cardiac mast cells: Pharmacological modulation of the local renin-angiotensin system

Current Pharmaceutical Design

Volumn 17, Issue 34, 2011, Pages 3744-3752

  Reid, Alicia C ^a   Brazin, Jacqueline A ^a   Morrey, Christopher ^b   Silver, Randi B ^a   Levi, Roberto ^b  

^a Departments of Physiology and Biophysics   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Arrhythmias; Cardiac renin angiotensin system; Mast cell rennin; Myocardial ischemia reperfusion; Norepinephrine; Sensory and sympathetic nerve endings; Sodium proton exchanger

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; CATHEPSIN D; CHYMASE; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; PRORENIN RECEPTOR; RENIN; SOMATOMEDIN B RECEPTOR;

ARTICLE; BINDING AFFINITY; CARDIAC MAST CELL; CELL FUNCTION; CELLULAR DISTRIBUTION; ENZYME DEGRADATION; EXOCYTOSIS; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HISTAMINE RELEASE; HORMONE SYNTHESIS; HUMAN; INTRACELLULAR SPACE; LYMPH NODE; MAST CELL; MAST CELL DEGRANULATION; NONHUMAN; PANCREAS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; SENSORY NERVE; SYMPATHETIC NERVE;

EID: 83455261818     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798357908     Document Type: Article

References (136)

1. Schomig A. Catecholamines in myocardial ischemia. Systemic and cardiac release. Circulation 1990; 82: II13-22.
2. Meredith IT, Broughton A, Jennings GL, Esler MD. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 1991; 325: 618-24.
3. 3-receptors: A new frontier in myocardial ischemia. J Pharmacol Exp Ther 2000; 292: 825-30.
4. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R. Sympathetic activation in congestive heart failure: evidence, consequences and therapeutic implications. Curr Vasc Pharmacol 2009; 7: 137-45.
5. 1 receptors to neuronal NHE activity and carriermediated norepinephrine release in myocardial ischemia. Am J Physiol Heart Circ Physiol 2004; 286: H1448-H1454.
6. Mackins CJ, Kano S, Seyedi N, et al. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest 2006; 116: 1063-70.
7. Reid AC, Silver RB, Levi R. Renin: at the heart of the mast cell. Immunol Rev 2007; 217: 123-40.
8. Silver RB, Reid AC, Brazin JA, Levi R. In: Joseph J., Ed. Mast Cells and Cardiovascular Disease. New York: Nova Science Publishers, Inc. 2010; pp. 5-32.
9. Koda K, Salazar-Rodriguez M, Corti F, et al. Aldehyde dehydrogenase activation prevents reperfusion arrhythmias by inhibiting local renin release from cardiac mast cells. Circulation 2010; 122: 771-81.
10. 3-receptor agonists in myocardial infarction. Exp Opin Invest Drugs 2000; 9: 2537-42.
11. 3-receptor-mediated inhibition of calcitonin gene-related peptide release from cardiac C fibers - A regulatory negative-feedback loop. Circ Res 1996; 78: 863-9.
12. Silver RB, Reid AC, Mackins CJ, et al. Mast cells: A unique source of renin. Proc Natl Acad Sci U S A 2004; 101: 13607-12.
13. Morrey C, Brazin J, Seyedi N, Corti F, Silver RB, Levi R. Interaction between Sensory C-fibers and Cardiac Mast Cells in Ischemia/Reperfusion: Activation of a Local Renin-Angiotensin System Culminating in Severe Arrhythmic Dysfunction. J Pharmacol Exp Ther 2010; 335: 76-84.
14. Frangogiannis NG, Entman ML. In: Marone, G., Lichtenstein, L.M., Galli, S.J., Eds. Mast Cells and Basophils. San Diego: Academic Press 2000; pp. 507-22.
15. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53: 31-47.
16. Steiner DRS, Gonzalez NC, Wood JG. Mast cells mediate the microvascular inflammatory response to systemic hypoxia. J Appl Physiol 2003; 94: 325-34.
17. Swindle EJ, Metcalfe DD. The role of reactive oxygen species and nitric oxide in mast cell-dependent inflammatory processes. Immunol Rev 2007; 217: 186-205.
18. Levi R. In: Marone, G., Lichtenstein, L.M., Condorelli, M., Fauci, A.S., Eds. Human Inflammatory Disease, Clinical Immunology. Toronto: B. C. Decker, Inc. 1988; pp. 93-105.
19. Kano S, Tyler E, Salazar-Rodriguez M, et al. Immediate Hypersensitivity Elicits Renin Release from Cardiac Mast Cells. Int Arch Allergy Immunol 2007; 146: 71-5.
20. Veerappan A, Reid AC, Estephan R, et al. Mast cell renin and a local renin-angiotensin system in the airway: Role in bronchoconstriction. Proc Natl Acad Sci U S A 2008; 105: 1315-20.
21. 3-receptors in myocardial ischemia: their role as regulators of exocytotic norepinephrine release. J Pharmacol Exp Ther 1994; 271: 1259-66.
22. 33-receptors in the human heart. Circ Res 1995; 77: 206-10.
23. Patella V, Marinò I, Arbustini E, et al. Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation 1998; 97: 971-8.
24. 1 receptor blockade in experimental myocardial ischemia/reperfusion. J Am Soc Nephrol 1999; 10 Suppl 11: S129-S136.
25. Chester AH. Mast cells feel the strain. Cardiovasc Res 2002; 55: 13-5.
26. 3-receptors inhibits carrier-mediated norepinephrine release during protracted myocardial ischemia - Comparison with adenosine A1-receptors and a2-adrenoceptors. Circ Res 1996; 78: 475-81.
27. 3 receptors. Mol Pharmacol 2003; 63: 378-82.
28. 3-receptors. Biochem Biophys Res Commun 2003; 306: 792-6.
29. Vaughan PF, Peers C, Walker JH. The use of the human neuroblastoma SH-SY5Y to study the effect of second messengers on noradrenaline release. Gen Pharmacol 1995; 26: 1191-201.
30. + exchange: A novel protective mechanism in myocardial ischemia. Proc Natl Acad Sci USA 2001; 98: 2855-9.
31. Seyedi N, Koyama M, Mackins CJ, Levi R. Ischemia promotes renin activation and angiotensin formation in sympathetic nerve terminals isolated from the human heart: contribution to carriermediated norepinephrine release. J Pharmacol Exp Ther 2002; 302: 539-44.
32. Sesti C, Koyama M, Broekman MJ, Marcus AJ, Levi R. Ectonucleotidase in sympathetic nerve endings modulates ATP and norepinephrine exocytosis in myocardial ischemia. J Pharmacol Exp Ther 2003; 306: 238-44.
33. 2+ Channels. J Pharmacol Exp Ther 2008; 326: 871-8.
34. 3-receptors inhibits carrier-mediated norepinephrine release in a human model of protracted myocardial ischemia. J Pharmacol Exp Ther 1997; 283: 494-500.
35. Schömig A, Kurz T, Richardt G, Schomig E. Neuronal sodium homoeostasis and axoplasmic amine concentration determine calcium-independent noradrenaline release in normoxic and ischemic rat heart. Circ Res 1988; 63: 214-26.
36. Dart AM, Riemersma RA. Effects of acidosis on anoxic and exocytotic noradrenaline release from the heart. J Mol Cell Cardiol 1989; 21: 75-83.
37. Benedict CR, Shelton B, Johnstone DE, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 1996; 94: 690-7.
38. Selwyn AP, Braunwald E. In: Braunwald E., Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, Eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill 2001; pp. 1399-410.
39. Esler M, Kaye D. Measurement of sympathetic nervous system activity in heart failure: the role of norepinephrine kinetics. Heart Fail Rev 2000; 5: 17-25.
40. Julius S, Nesbitt S. Sympathetic overactivity in hypertension. A moving target. Am J Hypertens 1996; 9: 113S-20S.
41. Esler M. The sympathetic system and hypertension. Am J Hypertens 2000; 13: 99S-105S.
42. Grassi G, Quarti-Trevano F, Dell'Oro R, Mancia G. Essential hypertension and the sympathetic nervous system. Neurol Sci 2008; 29 Suppl 1: S33-6.
43. Chieffi BG, De Paulis A, Di Matteo L, Gentile M, Marone G, Minucci S. In situ characterization of mast cells in the frog Rana esculenta. Cell Tissue Res 1998; 292: 151-62.
44. Ghanem NS, Assem ES, Leung KB, Pearce FL. Cardiac and renal mast cells: morphology, distribution, fixation and staining properties in the guinea pig and preliminary comparison with human. Agents Actions 1988; 23: 223-6.
45. Frangogiannis NG, Burns AR, Michael LH, Entman ML. Histochemical and morphological characteristics of canine cardiac mast cells. Histochem J 1999; 31: 221-9.
46. Forman MB, Oates JA, Robertson D, Robertson RM, Roberts LJ, Virmani R. Increased adventitial mast cells in a patient with coronary spasm. N Engl J Med 1985; 313: 1138-41.
47. Dvorak AM. Mast-cell degranulation in human hearts. N Engl J Med 1986; 315: 969-70.
48. Marone G, De Crescenzo G, Adt M, Patella V, Arbustini E, Genovese A. Immunological characterization and functional importance of human heart mast cells. Immunopharmacology 1995; 31: 1-18.
49. Krishnaswamy G, Ajitawi O, Chi DS. The human mast cell: an overview. Methods Mol Biol 2005; 315: 13-34.
50. Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev 1977; 57: 313-70.
51. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest 1987; 79: 1-6.
52. Dostal DE, Baker KM. The cardiac renin-angiotensin system - Conceptual, or a regulator of cardiac function? Circ Res 1999; 85: 643-50.
53. Bader M. Role of the local renin-angiotensin system in cardiac damage: a minireview focussing on transgenic animal models. J Mol Cell Cardiol 2002; 34: 1455-62.
54. Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: Potential roles in cardiovascular and renal regulation. Endocr Rev 2003; 24: 261-71.
55. Campbell DJ. Critical Review of Prorenin and (Pro)renin Receptor Research. Hypertension 2008; 51: 1259-64.
56. Danser AHJ. Local renin-angiotensin systems: the unanswered questions. Int J Biochem Cell Biol 2003; 35: 759-68.
57. Vane JR. The release and fate of vaso-active hormones in the circulation. Br J Pharmacol 1969; 35: 209-42.
58. Barlucchi L, Leri A, Dostal DE, et al. Canine ventricular myocytes possess a renin-angiotensin system that is upregulated with heart failure. Circ Res 2001; 88: 298-304.
59. Bader M, Peters J, Baltatu O, Müller DN, Luft FC, Ganten D. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J Mol Med 2001; 79: 76-102.
60. Neri-Serneri GG, Boddi M, Coppo M, et al. Evidence for the existence of a functional cardiac renin- angiotensin system in humans. Circulation 1996; 94: 1886-93.
61. Muller DN, Fischli W, Clozel JP, et al. Local angiotensin II generation in the rat heart: role of renin uptake. Circ Res 1998; 82: 13-20.
62. Van Kats JP, Danser AHJ, Van Meegen JR, Sassen MA, Verdouw PD, Schalekamp MADH. Angiotensin production by the heart - A quantitative study in pigs with the use of radiolabeled angiotensin infusions. Circulation 1998; 98: 73-81.
63. Dell'italia LJ, Meng QC, Balcells E, et al. Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces. J Clin Invest 1997; 100: 253-8.
64. de Lannoy LM, Schuijt MP, Saxena PR, Schalekamp MADH, Danser AHJ. Angiotensin converting enzyme is the main contributor to angiotensin I-II conversion in the interstitium of the isolated perfused rat heart. J Hypertens 2001; 19: 959-65.
65. Dzau VJ. Implications of local angiotensin production in cardiovascular physiology and pharmacology. Am J Cardiol 1987; 59: 59A-65A.
66. Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG. Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. Am J Physiol Heart Circ Physiol 2001; 281: H2337-H2365.
67. Gavras H, Brunner HR. Role of angiotensin and its inhibition in hypertension, ischemic heart disease, and heart failure. Hypertension 2001; 37: 342-5.
68. Kaschina E, Scholz H, Steckelings UM, et al. Transition from atherosclerosis to aortic aneurysm in humans coincides with an increased expression of RAS components. Atherosclerosis 2009; 205: 396-403.
69. Ihara M, Urata H, Shirai K, et al. High cardiac angiotensin-IIforming activity in infarcted and non-infarcted human myocardium. Cardiology 2000; 94: 247-53.
70. Maruyama R, Hatta E, Yasuda K, Smith NCE, Levi R. ACEIndependent angiotensin formation in a human model of myocardial ischemia: modulation of norepinephrine release by AT1 and AT2 receptors. J Pharmacol Exp Ther 2000; 294: 248-62.
71. Wei CC, Hase N, Inoue Y, et al. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest 2010; 120: 1229-39.
72. Hirsch AT, Opsahl JA, Lunzer MM, Katz SA. Active renin and angiotensinogen in cardiac interstitial fluid after myocardial infarction. Am J Physiol Heart Circ Physiol 1999; 276: H1818-H1826.
73. Von Lutterotti N, Catanzaro DF, Sealey JE, Laragh JH. Renin is not synthesized by cardiac and extrarenal vascular tissues: A review of experimental evidence. Circulation 1994; 89: 458-70.
74. Katz SA, Opsahl JA, Lunzer MM, Forbis LM, Hirsch AT. Effect of Bilateral Nephrectomy on Active Renin, Angiotensinogen, and Renin Glycoforms in Plasma and Myocardium. Hypertension 1997; 30: 259.
75. Trolliet MR, Phillips MI. The effect of chronic bilateral nephrectomy on plasma and brain angiotensin. J Hypertens 1992; 10: 29-36.
76. Veerappan A, Reid AC, O'Connor N, et al. Mast Cells are Required for the Development of Renal Fibrosis in theRodent Unilateral Ureteral Obstruction Model. Am J Physiol Renal Physiol 2011; In Press.
77. Krop M, Van Veghel R, Garrelds IM, et al. Cardiac Renin Levels Are Not Influenced by the Amount of Resident Mast Cells. Hypertension 2009; 54: 315-21.
78. Pardanani A, Lim KH, Lasho TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 2009; 114: 3769-72.
79. Bispo-da-Silva LB, Sivieri DO, Jr., Prado CM, et al. Cardiac mast cell proteases do not contribute to the regulation of the rat coronary vascular responsiveness to arterial delivered angiotensin I and II. Vascul Pharmacol 2010; 53: 22-7.
80. Pool JL. Direct renin inhibition: focus on aliskiren. J Manag Care Pharm 2007; 13: 21-33.
81. Uehara Y, Urata H, Sasaguri M, et al. Increased chymase activity in internal thoracic artery of patients with hypercholesterolemia. Hypertension 2000; 35: 55-60.
82. Hackenthal E, Hackenthal R, Hilgenfeldt U. Isorenin, pseudorenin, cathepsin D and renin. A comparative enzymatic study of angiotensin-forming enzymes. Biochim Biophys Acta 1978; 522: 574-88.
83. Wu Q, Kuo HC, Deng GG. Serine proteases and cardiac function. Biochim Biophys Acta 2005; 1751: 82-94.
84. Urata H, Boehm KD, Philip A, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993; 91: 1269-81.
85. Liao Y, Husain A. The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases. Can J Cardiol 1995; 11 Suppl F: 13F-9F.
86. Doggrell SA, Wanstall JC. Cardiac chymase: pathophysiological role and therapeutic potential of chymase inhibitors. Can J Physiol Pharmacol 2005; 83: 123-30.
87. Kunori Y, Muroga Y, Iidaka M, Mitsuhashi H, Kamimura T, Fukamizu A. Species differences in angiotensin II generation and degradation by mast cell chymases. J Recept Signal Transduct Res 2005; 25: 35-44.
88. Miyazaki M, Takai S, Jin D, Muramatsu M. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther 2006.
89. Kokkonen JO, Lindstedt KA, Kovanen PT. Role for chymase in heart failure - Angiotensin II-dependent or -independent mechanisms? Circulation 2003; 107: 2522-4.
90. Matsumoto T, Wada A, Tsutamoto T, Ohnishi M, Isono T, Kinoshita M. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 2003; 107: 2555-8.
91. Ihara M, Urata H, Kinoshita A, et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999; 33: 1399-405.
92. Nguyen G, Delarue F, Berrou J, Rondeau E, Sraer JD. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int 1996; 50: 1897-903.
93. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-27.
94. Nguyen G. The (pro)renin receptor in health and disease. Ann Med 2010; 42: 13-8.
95. Geoffrey R, Jia S, Kwitek AE, et al. Evidence of a functional role for mast cells in the development of type 1 diabetes mellitus in the BioBreeding rat. J Immunol 2006; 177: 7275-86.
96. van Kesteren CA, Danser AH, Derkx FH, et al. Mannose 6-phosphate receptor-mediated internalization and activation of prorenin by cardiac cells. Hypertension 1997; 30: 1389-96.
97. Saris JJ, Derkx FH, Lamers JM, Saxena PR, Schalekamp MA, Danser AH. Cardiomyocytes bind and activate native human prorenin: role of soluble mannose 6-phosphate receptors. Hypertension 2001; 37: 710-5.
98. Saris JJ, Derkx FH, de Bruin RJ, et al. High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin. Am J Physiol Heart Circ Physiol 2001; 280: H1706-H1715.
99. Admiraal PJ, van Kesteren CA, Danser AH, Derkx FH, Sluiter W, Schalekamp MA. Uptake and proteolytic activation of prorenin by cultured human endothelial cells. J Hypertens 1999; 17: 621-9.
100. Op den Brouw ML, Binda RS, Geijtenbeek TB, Janssen HL, Woltman AM. The mannose receptor acts as hepatitis B virus surface antigen receptor mediating interaction with intrahepatic dendritic cells. Virology 2009; 393: 84-90.
101. Xaplanteri P, Lagoumintzis G, Dimitracopoulos G, Paliogianni F. Synergistic regulation of Pseudomonas aeruginosa-induced cytokine production in human monocytes by mannose receptor and TLR2. Eur J Immunol 2009; 39: 730-40.
102. Danser AHJ, Deinum J. Renin, Prorenin and the Putative (Pro)renin Receptor. Hypertension 2005; 46: 1069-76.
103. Kruger PG, Ellingsen T, Saetersdal TS. Response of rat myocardial mast cells to experimental ischemia. J Exp Pathol 1990; 5: 29-38.
104. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. AT(2) receptors: Functional relevance in cardiovascular disease. Pharmacol Ther 2008; 120: 292-316.
105. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 2003; 100: 8258-63.
106. Ferreira AJ, Santos RA. Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res 2005; 38: 499-507.
107. Sampaio WO, Souza dos Santos RA, Faria-Silva R, et al. Angiotensin-(1-7) Through Receptor Mas Mediates Endothelial Nitric Oxide Synthase Activation via Akt-Dependent Pathways. Hypertension 2007; 49: 185-92.
108. Xu J, Carretero OA, Liu YH, et al. Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice. Hypertension 2002; 40: 244-50.
109. Gondo N, Kumagai K, Nakashima H, Saku K. Angiotensin II provokes cesium-induced ventricular tachyarrhythmias. Cardiovasc Res 2001; 49: 381-90.
110. Iravanian S, Dudley SC, Jr. The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm 2008; 5: S12-S17.
111. Swindle EJ, Hunt JA, Coleman JW. A comparison of reactive oxygen species generation by rat peritoneal macrophages and mast cells using the highly sensitive real-time chemiluminescent probe pholasin: inhibition of antigen-induced mast cell degranulation by macrophage-derived hydrogen peroxide. J Immunol 2002; 169: 5866-73.
112. Heneberg P, Dráber P. Regulation of cys-based protein tyrosine phosphatases via reactive oxygen and nitrogen species in mast cells and basophils. Curr Med Chem 2005; 12: 1859-71.
113. Inoue T, Suzuki Y, Yoshimaru T, Ra C. Reactive oxygen species produced up- or downstream of calcium influx regulate proinflammatory mediator release from mast cells: role of NADPH oxidase and mitochondria. Biochim Biophys Acta 2008; 1783: 789-802.
114. Chodaczek G, Bacsi A, Dharajiya N, Sur S, Hazra TK, Boldogh I. Ragweed pollen-mediated IgE-independent release of biogenic amines from mast cells via induction of mitochondrial dysfunction. Mol Immunol 2009; 46: 2505-14.
115. 2+ channel activity. Mol Immunol 2009; 46: 2200-9.
116. Cinci L, Masini E, Bencini A, Valtancoli B, Mastroianni R, Calosi L, Bani D. Suppression of allergen-induced respiratory dysfunction and airway inflammation in sensitized guinea pigs by Mn(II)(Me(2)DO2A), a novel superoxide scavenger compound. Free Radic Biol Med 2010; 48: 1525-34.
117. Heneberg P, Dráberová L, Bambousková M, Pompach P, Dráber P. Down-regulation of protein-tyrosine phosphatases activates an immune receptor in the absence of its translocation into lipid rafts. J Biol Chem 2010; 285: 12787-802.
118. Wolff AA, Levi R. Histamine and cardiac arrhythmias. Circ Res 1986; 58: 1-16.
119. Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 2008; 7: 41-53.
120. 3-receptor. Agents Actions 1990; 30: 13-23.
121. 2+ channels. J Pharmacol Exp Ther 1994; 269: 221-9.
122. 3-receptors in a canine model of pacing-induced heart failure: a cause of increased norepinephrine release? Circulation 1996; 94: I-406.
123. Kübler W, Strasser RH. Signal transduction in myocardial ischaemia. Eur Heart J 1994; 15: 437-45.
124. + in neuronal uptake: kinetic evidence for cotransport. Naunyn Schmiedebergs Arch Pharmacol 1979; 309: 99-107.
125. 3-receptor-induced attenuation of norepinephrine exocytosis from cardiac sympathetic nerve endings. Proc Natl Acad Sci USA 2002; 99: 501-6.
126. 3-receptor-induced attenuation of norepinephrine exocytosis: a decreased PKA activity mediates a reduction in intracellular calcium. J Pharmacol Exp Ther 2005; 312: 272-80.
127. 3R pathway. Biochem Pharmacol 2007; 73: 1146-56.
128. + exchanger activity: signalling and significance. Cardiovasc Res 2003; 57: 942-52.
129. Grassi G, Arenare F, Pieruzzi F, Brambilla G, Mancia G. Sympathetic activation in cardiovascular and renal disease. J Nephrol 2009; 22: 190-5.
130. Harada K, Komuro I, Hayashi D, Sugaya T, Murakami K, Yazaki Y. Angiotensin II type 1a receptor is involved in the occurrence of reperfusion arrhythmias. Circulation 1998; 97: 315-7.
131. Yahiro E, Ideishi M, Wang LX, Urata H, Kumagai K, Arakawa K, Saku K. Reperfusion-induced arrhythmias are suppressed by inhibi tion of the angiotensin II type 1 receptor. Cardiology 2003; 99: 61-7.
132. Garg S, Narula J, Marelli C, Cesario D. Role of Angiotensin receptor blockers in the prevention and treatment of arrhythmias. Am J Cardiol 2006; 97: 921-5.
133. Von Lewinski D, Kockskamper J, Rubertus SU, et al. Direct proarrhythmogenic effects of angiotensin II can be suppressed by AT1 receptor blockade in human atrial myocardium. Eur J Heart Fail 2008; 10: 1172-6.
134. Maruyama R, Hatta E, Levi R. Norepinephrine release and ventricular fibrillation in myocardial ischemia/reperfusion: Roles of angiotensin and bradykinin. J Cardiovasc Pharmacol 1999; 34: 913-5.
135. Brooks AC, Whelan CJ, Purcell WM. Reactive oxygen species generation and histamine release by activated mast cells: modulation by nitric oxide synthase inhibition. Br J Pharmacol 1999; 128: 585-90.
136. Swindle EJ, Metcalfe DD, Coleman JW. Rodent and human mast cells produce functionally significant intracellular reactive oxygen species but not nitric oxide. J Biol Chem 2004; 279: 48751-9.